• IgD/dextran conjugate-mediated B-cell activation using flow cytometry in whole blood
  • Species: Rat

B cells contribute greatly in the development and expression of autoimmunity. Depletion of B cells and blocking B-cell activation are beneficial in reducing autoimmune conditions in human and animal disease models. Following B-cell activation, the up-regulation of CD86 on a B-cell surface is observed within 6 hours and peaks at around 24 hours. Inhibitors specific for B cell receptor (BCR)-initiated activation cascades block BCR-dependent CD86 expression in humans and mice. Thus, the effect of the inhibitors on CD86 expression correlates well with their effect on reduction of disease development.

How can we support your program?

To evaluate the effect of a compound in an ex vivo model of B-cell CD86 activation after in vivo compound dosing, we collect whole blood at various time points and evaluate the presence of CD86 on B cell surface by flow cytometry.